Jazz Pharmaceuticals JAZZ Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue from Contract with Customer, Excluding Assessed Tax by Product | ||||||
| Defitelio/defibrotide | $47.4M+16.5% | $58.87M+2.1% | $51.75M-21.4% | $48.11M+5.9% | $40.7M-14.6% | |
| Epidiolex/Epidyolex | $249.8M+14.7% | $287.12M+4.4% | $302.61M+20.3% | $251.73M+1.9% | $217.7M+9.6% | |
| High-sodium oxybate AG royalty revenue | $36.3M-25.8% | $55.7M+0.7% | $52.95M-9.0% | $54.14M0.0% | $48.9M-2.1% | |
| Modeyso | $41.4M— | $36.54M— | $11.03M— | $470K— | $0— | |
| Other | $2.7M-73.8% | $3.31M+11.3% | $2.14M-3.9% | $4.41M+63.4% | $10.3M+189% | |
| Other royalty and contract revenues | $7.3M-23.2% | —— | $8.75M+23.2% | $6M+8.8% | $9.5M-4.4% | |
| Rylaze/Enrylaze | $103.7M+10.1% | $108.16M+6.6% | $99.87M+1.1% | $100.66M-6.6% | $94.2M-8.3% | |
| Vyxeos | $26.6M-9.8% | $34.73M-34.8% | $37.58M+9.5% | $44.85M+4.3% | $29.5M-7.9% | |
| Xyrem | $31.2M-16.1% | $37.78M-23.3% | $35.66M-38.6% | $35.35M-43.2% | $37.2M-42.1% | |
| Xywav | $408.2M+18.4% | $465.45M+16.1% | $431.41M+11.1% | $415.32M+12.7% | $344.8M+9.4% | |
| Zepzelca | $101M+60.3% | $90.44M+15.5% | $79.3M-7.6% | $74.54M-8.0% | $63M-16.1% | |
| Ziihera | $13.3M+565% | $8.54M+712% | $8.31M— | $5.99M— | $2M— | |
| Number of patents, paragraph IV certification notice filed by Product | ||||||
| Xyrem | 7— | —— | —— | —— | —— | |
| Xywav | 15— | —— | —— | —— | —— | |
| Revenue from Contract with Customer, Excluding Assessed Tax by Geography | ||||||
| All other | $16.7M+2.5% | $32.69M+0.1% | $19.23M-19.8% | $26.67M+56.2% | $16.3M-27.3% | |
| Europe | $92.4M+10.5% | $88.92M+8.6% | $86.41M+11.8% | $82.76M+0.7% | $83.6M+17.2% | |
| U.S. | $959.8M+20.3% | $1.08B+10.5% | $1.02B+7.0% | $936.28M+1.3% | $797.9M-1.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Jazz Pharmaceuticals break its business down?
- Jazz Pharmaceuticals (JAZZ) reports revenue from contract with customer, excluding assessed tax by product across 12 parts — Defitelio/defibrotide, Epidiolex/Epidyolex, High-sodium oxybate AG royalty revenue, Modeyso and Other. Each is extracted from the segment footnotes and tracked over time.
- Where does Jazz Pharmaceuticals's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Jazz Pharmaceuticals's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
